IceCure Medical publishes investor presentation on ProSense FDA-cleared cryoablation treatment for low-risk breast cancer

IceCure Medical Ltd.

IceCure Medical Ltd.

ICCM

0.00
  • IceCure outlined U.S. commercialization plans for its ProSense cryoablation system, positioned as the only on-label minimally invasive local treatment for low-risk breast cancer.
  • Management pegged the U.S. breast cancer opportunity at more than $1.2 billion in total addressable market, citing an 8+ year competitive head start.
  • ICE3 breast cancer study data cited 4.3% ipsilateral recurrence at 5 years, 96.7% survival, 24-hour recovery, no re-excision.
  • FDA-cleared post-marketing ChoICE study planned for about 400 patients at at least 30 U.S. sites, with initiation targeted for H2 2026.
  • Company cited regulatory approvals in 27 countries, 47 granted patents, 64 employees, manufacturing capacity positioned to scale.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on July 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.